JPRN-jRCT1031230157招募中Unknown
A randomized, single-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of a dietary supplement containing wine processing residue powder in healthy adult women
Hida Noriko0 个研究点目标入组 45 人开始时间: 2023年6月21日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 40age old 至 < 60age old（—）
- 性别
- Female
入选标准
- •Persons who meet all of the following criteria shall be eligible.
- •1) Persons who are between 40 and 60 years of age at the time consent is obtained.
- •3) Persons who are capable of consenting, abide by the rules of compliance during participation in the research, undergo the preliminary examination specified in the research protocol, and are able to report subjective symptoms, etc.
- •4) Persons who have been judged by the physician in charge of the research to be eligible to participate in this study based on the preliminary examination specified in the research protocol.
排除标准
- •Persons who have any of the following will not be included in this study
- •1) Persons with a history of drug abuse or dependence, alcohol abuse or dependence, or heart, liver, renal, pulmonary, ocular, or hematologic disease that may affect the safety or the evaluation of this study.
- •2) Patients who are taking drugs (including dietary supplements and dietary supplements) that may affect the evaluation and safety of this study.
- •3) Have a history of drug allergy
- •4) Persons who regularly use excessive amounts of alcohol (those who cannot maintain abstinence from alcohol during the study period)
- •5) Those who are within 3 months of participating in another clinical research study
- •6) Other subjects who are judged by the investigator to be ineligible for this study.
研究者
相似试验
进行中（未招募）
1 期
A randomized, double-blind, placebo-controlled, parallel group trial of HMR1766 assessing the efficacy and safety of 3 doses of HMR1766 (25, 100, 200 mg OD) versus placebo with cilostazol, 100 mg BID as a calibrator, administered for 26 weeks in patients with Peripheral Arterial Disease (PAD) Fontaine stage II. - ACCELAPeripheral Arterial Disease (PAD) Fontaine stage II (intermittent claudication)MedDRA version: 8.1Level: LLTClassification code 10022562Term: Intermittent claudicationEUCTR2006-004275-35-FRsanofi-aventis recherche & développement550
进行中（未招募）
不适用
A study to determine the appropriate dose(s) of Dupilumab (REGN668)in adult patients with moderate to severe atopic dermatitis (eczema)Atopic dermatitsMedDRA version: 16.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858EUCTR2012-003651-11-PLRegeneron Pharmaceuticals, Inc.240
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, parallel group trial of HMR1766 assessing the efficacy and safety of 3 doses of HMR1766 (25, 100, 200 mg OD) versus placebo with cilostazol, 100 mg BID as a calibrator, administered for 26 weeks in patients with Peripheral Arterial Disease (PAD) Fontaine stage II. - ACCELAPeripheral Arterial Disease (PAD) Fontaine stage II (intermittent claudication)MedDRA version: 8.1Level: LLTClassification code 10022562Term: Intermittent claudicationEUCTR2006-004275-35-ATsanofi-aventis recherche & développement550
进行中（未招募）
1 期
Efficacy and safety of dexketoprofen trometamol and tramadol hydrochloride combination on moderate to severe acute pain in patients with acute low back paiow back painMedDRA version: 21.0Level: LLTClassification code 10024891Term: Low back painSystem Organ Class: 100000004859EUCTR2019-003656-37-ESMenarini International Operations Luxembourg SA538
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with traditional DMARD therapy in patients with moderate to severe active rheumatoid arthritis and an inadequate response to current DMARD therapy.Rheumatoid ArthritisEUCTR2004-005210-37-DEF. Hoffmann La-Roche AG1,200